SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila gets final approval from USFDA for Nifedipine, Cholestyramine

03 Jul 2018 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Nifedipine Extended-Release Tablets USP (Adalat CC) in the strengths of 30 mg, 60 mg, and 90 mg. It is used to treat high blood pressure and angina (chest pain brought on by exercise or stress). It works to control blood pressure and reduce the number of angina attacks by relaxing blood vessels.  Nifedipine will be manufactured at the group’s manufacturing facility at Moraiya, Ahmedabad.

The group also received the final approval to market Cholestyramine for Oral Suspension USP (Questran), 4 g resin per pouch or scoopful. It is used along with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks. It will be manufactured at the group’s formulations manufacturing facility at Baddi. In line with this, the group has now has 201 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

929.75 -17.35 (-1.83%)
24-Apr-2026 11:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1624.95
Dr. Reddys Lab 1317.90
Cipla 1287.20
Zydus Lifesciences 929.75
Lupin 2294.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×